Inspire Investing, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Inspire Investing, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$151.41 - $196.57 $51,327 - $66,637	339 Added 2.52%	13,797 $2.64 Million
Q3 2023 Oct 26, 2023	SELL	$170.77 - $211.65 $1.09 Million - $1.35 Million	-6,401 Reduced 32.23%	13,458 $2.38 Million
Q2 2023 Jul 31, 2023	BUY	$185.01 - $212.05 $629,774 - $721,818	3,404 Added 20.69%	19,859 $3.77 Million
Q1 2023 Apr 24, 2023	BUY	$182.66 - $235.53 $297,918 - $384,149	1,631 Added 11.0%	16,455 $3.3 Million
Q4 2022 Jan 26, 2023	BUY	$185.53 - $241.31 $250,836 - $326,251	1,352 Added 10.04%	14,824 $0
Q3 2022 Nov 07, 2022	SELL	$138.54 - $232.0 $155,996 - $261,232	-1,126 Reduced 7.71%	13,472 $2.7 Million
Q2 2022 Aug 10, 2022	SELL	$120.42 - $169.29 $136,676 - $192,144	-1,135 Reduced 7.21%	14,598 $2.13 Million
Q1 2022 Apr 21, 2022	SELL	$127.18 - $173.91 $356,485 - $487,469	-2,803 Reduced 15.12%	15,733 $2.57 Million
Q4 2021 Feb 14, 2022	BUY	$159.56 - $209.29 $2.96 Million - $3.88 Million	18,536 New	18,536 $3.14 Million
Q4 2021 Feb 03, 2022	SELL	$159.56 - $209.29 $2.35 Million - $3.09 Million	-14,755 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$169.75 - $207.73 $2.5 Million - $3.07 Million	14,755 New	14,755 $2.79 Million

642

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Inspire Investing, LLC, based on Form 13F filings with the SEC.

Stay updated on Inspire Investing, LLC with notifications on news.